Glucagon and a glucagon-GLP-1 dual-agonist increases cardiac performance with different metabolic effects in insulin-resistant hearts

British Journal of Pharmacology

Volumn 165, Issue 8, 2012, Pages 2736-2748

  Axelsen, L N ^a,b,c   Keung, W ^a   Pedersen, H D ^b,e   Meier, E ^b   Riber, D ^b   Kjolbye A L ^b   Petersen, J S ^b   Proctor, S D ^d   Holstein Rathlou, N H ^c   Lopaschuk, G D ^a  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b Zealand Pharma AS   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY OF ALBERTA   (Canada)

^e NOVO NORDISK A S   (Denmark)

Author keywords

Cardiac energetics; Cardiac function; Cardiac metabolism; Diabetic cardiomyopathy; GLP 1; Glucagon; Glucagon GLP 1 dual agonist; Inotropic compounds; Insulin resistance; Working hearts

Indexed keywords

ACYL COENZYME A; ADENOSINE DIPHOSPHATE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INOTROPIC AGENT; NUCLEOTIDE; PALMITIC ACID; UNCLASSIFIED DRUG; ZP 131; ZP 2495;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENERGY METABOLISM; GLUCOSE OXIDATION; GLYCOLYSIS; HEART FUNCTION; HEART MUSCLE METABOLISM; HEART PERFORMANCE; HEART PERFUSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INSULIN RESISTANCE; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADENOSINE TRIPHOSPHATE; ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE; GLYCOLYSIS; HEART; HEART RATE; HEK293 CELLS; HUMANS; INSULIN RESISTANCE; MALE; OXIDATION-REDUCTION; PALMITATES; PEPTIDES; RATS;

EID: 84859023464     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01714.x     Document Type: Article

References (32)

1. Ally A, Park G (1992). Rapid determination of creatine, phosphocreatine, purine bases and nucleotides (ATP, ADP, AMP, GTP, GDP) in heart biopsies by gradient ion-pair reversed-phase liquid chromatography. J Chromatogr 575: 19-27.
2. Atkinson LL, Kozak R, Kelly SE, Onay-Besikci A, Russell JC, Lopaschuk GD (2003). Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab 284: E923-E930. (Pubitemid 36444027)
3. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M (2008). Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117: 2340-2350. (Pubitemid 351653542)
4. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R et al. (2007). Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115: 114-126. (Pubitemid 46058619)
5. Buse MG, Biggers JF, Drier C, Buse JF (1973). The effect of epinephrine, glucagon, and the nutritional state on the oxidation of branched chain amino acids and pyruvate by isolated hearts and diaphragms of the rat. J Biol Chem 248: 697-706.
6. Cook SA, Aitman T, Naoumova RP (2005). Therapy insights: heart disease and the insulin-resistant patient. Nat Clin Pract Cardiovasc Med 2: 252-260. (Pubitemid 40846497)
7. Echtay KS, Roussel DS, Pierre J, Jekabsons MB, Cadenas S, Stuart JA et al. (2002). Superoxide activates mitochondrial uncoupling proteins. Nature 415: 96-99. (Pubitemid 34062457)
8. Farah A, Tuttle R (1960). Studies on the pharmacology of glucagon. J Pharmacol Exp Ther 129: 49-55.
9. Grieve DJ, Cassidy RS, Green BD (2009). Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br J Pharmacol 157: 1340-1351.
10. Hamad E, Mather PJ, Srinivasan S, Rubin S, Whellan DJ, Feldman AM (2007). Pharmacological therapy of chronic heart failure. Am J Cardiovasc Drugs 7: 235-248. (Pubitemid 47299050)
11. Holst JJ (2007). The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439.
12. Kenakin TP (1981). A pharmacological method to estimate the pKi of competitive inhibitors of agonist uptake processes in isolated tissues. Naunyn Schmiedebergs Arch Pharmacol 316: 89-95.
13. Kenakin TP (2001). Quantitation in receptor pharmacology. Receptors Channels 7: 371-385.
14. Kenakin T (2004). Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25: 186-192.
15. Kim JY, Lim DM, Moon CI, Jo KJ, Lee SK, Baik HW et al. (2010). Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3b activity. J Korean Med Sci 25: 1626-1632.
16. Levey GS, Epstein SE (1969). Activation of adenyl cyclase by glucagon in cat and human heart. Circ Res 24: 151-156.
17. Lopaschuk GD (2002). Metabolic abnormalities in the diabetic heart. Heart Fail Rev 7: 149-159.
18. Lopaschuk GD, Barr RL (1997). Measurements of fatty acid and carbohydrate metabolism in the isolated working rat heart. Mol Cell Biochem 172: 137-147. (Pubitemid 27374583)
19. Lopaschuk GD, Russell JC (1991). Myocardial function and energy substrate metabolism in the insulin-resistant JCR:LA corpulent rat. J Appl Physiol 71: 1302-1308.
20. MacLeod KM, Rodgers RL, McNeill JH (1981). Characterization of glucagon-induced changes in rate, contractility and cyclic AMP levels in isolated cardiac preparations of the rat and guinea pig. J Pharmacol Exp Ther 217: 798-804. (Pubitemid 11082272)
21. Mayer SE, Namm DH, Rice LUCI (1970). Effect of glucagon on cyclic 3′,5′-AMP, phosphorylase activity and contractility of heart muscle of the rat. Circ Res 26: 225-233.
22. Morabito D, Montessuit C, Rosenblatt-Velin N, Lerch R, Vallotton M, Lang U (2002). Impaired glucose metabolism in the heart of obese Zucker rats after treatment with phorbol ester. Int J Obes 26: 327-334. (Pubitemid 34226157)
23. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al. (2004a). Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109: 962-965. (Pubitemid 38282847)
24. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. (2004b). Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110: 955-961. (Pubitemid 39128621)
25. Nikolaidis LA, Elahi D, Shen YT, Shannon RP (2005). Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 289: H2401-H2408. (Pubitemid 41698549)
26. Oeseburg H, de Boer RA, Buikema H, van der Harst P, van Gilst WH, Sillje HHW (2010). Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A. Arterioscler Thromb Vasc Biol 30: 1407-1414.
27. Ossum A, van Deurs U, Engstrøm T, Jensen JS, Treiman M (2009). The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 60: 411-417.
28. Russell JC, Amy RM (1986). Early atherosclerotic lesions in a susceptible rat model the LA/N-corpulent rat. Atherosclerosis 60: 119-129. (Pubitemid 16053882)
29. Russell JC, Kelly SE, Proctor SD (2007). The JCR:LA-cp rat: animal model of the metabolic syndrome exhibiting micro- and macrovascular disease. In: Shafrir E (ed.). Animal Models of Diabetes. CRC Press, Taylor & Francis Group: Boca Raton, FL, pp. 159-183.
30. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP (2006). Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12: 694-699. (Pubitemid 44881367)
31. White CM (1999). A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol 39: 442-447.
32. Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT et al. (2006). Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317: 1106-1113. (Pubitemid 43764114)